Sector News

Boehringer aims to cut up to 600 jobs in Germany

September 23, 2014
Life sciences
(Reuters) – Drugmaker Boehringer Ingelheim said it plans to cut up to 600 jobs in Germany, citing healthcare budget cuts in the United States and a stricter reimbursement regime in Germany.
 
The unlisted family-controlled group, which collaborates on diabetes drugs with Eli Lilly, said in a statement on Tuesday the cutbacks were part of a drive to reduce costs in Germany by 15 percent or 450 million euros ($580 million).
 
The company, which makes stroke prevention pill Pradaxa, plans to cut between 500 and 600 jobs in Germany by the end of 2016, seeking to avoid forced redundancies.
 
Of its global workforce of 47,500, the group employs about 14,000 in Germany.
 
(1 US dollar = 0.7759 euro) (Reporting by Ludwig Burger; Editing by David Holmes)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”